Beijing University of Chinese Medicine, Beijing, China; Department of Cardiology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Department of Cardiology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, China.
Ann Palliat Med. 2021 Jul;10(7):7942-7959. doi: 10.21037/apm-21-1469.
The herbal pairing of Dangshen (DS) [Codonopsis pilosula (Franch.) Nannf.] and Huangqi (HQ) [Astragalus membranaceus (Fisch.) Bge.] (DHP) is a traditional Chinese herbal medicine that is frequently used to treat chronic heart failure (CHF) in China. However, the pharmacological mechanism of DHP has not been fully elucidated. This is the first study aimed to reveal the active mechanism of DHP in the treatment of CHF by using network pharmacology methods.
The active ingredients of DHP were obtained from the TCMSP database, and the potential targets of DHP were predicted using the SwissTargetPrediction database. CHF-related targets were searched by the DisGeNET and GeneCards databases. The common targets between the disease and herbs were obtained using a Venn diagram. The STRING database was utilized to obtain the protein-protein interaction data. Next, we used Cytoscape 3.7.2 software to construct and analyze the herb-ingredient-potential targets-disease network. Topology analysis was used to identify the key ingredients and hub genes. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed using the Metascape database to reveal the mechanism. Furthermore, molecular docking simulation was performed using AutoDock Vina software to assess the affinity of the key ingredients and hub genes.
Five key ingredients and six hub genes were screened. The six hub genes were closely related to PI3K /AKT or ERK1/2 pathways. The KEGG pathways mainly involved the TNF signaling pathway, calcium signaling pathway, and cancer-related pathways. The GO enrichment analysis results showed that DHP might act on biological processes including positive regulation of kinase activity and cellular response to nitrogen compound via the three above-mentioned pathways in the treatment of CHF. Finally, the molecular docking results showed that the five key ingredients exhibited strong affinities to the six hub genes.
This study revealed the molecular mechanism that the flavonoids in DHP may alleviate endothelial dysfunction and cardiac hypertrophy via regulation of the TNF pathway and its downstream PI3K/Akt or ERK1/2 signaling pathways, or improve excitation-contraction coupling by regulating calcium signaling pathway, thereby improving CHF. These results provide insights for further experimentation on its pharmacological effects.
党参(DS)[党参(Franch。)Nannf。]和黄芪(HQ)[黄芪(膜)(Bge。)](DHP)的草药配对是一种常用于中国治疗慢性心力衰竭(CHF)的中药。然而,DHP 的药理机制尚未完全阐明。这是第一项使用网络药理学方法揭示 DHP 治疗 CHF 活性机制的研究。
从 TCMSP 数据库中获取 DHP 的活性成分,并使用 SwissTargetPrediction 数据库预测 DHP 的潜在靶点。通过 DisGeNET 和 GeneCards 数据库搜索与 CHF 相关的靶点。使用 Venn 图获得疾病和草药之间的共同靶点。使用 STRING 数据库获取蛋白质-蛋白质相互作用数据。接下来,我们使用 Cytoscape 3.7.2 软件构建和分析草药-成分-潜在靶点-疾病网络。拓扑分析用于识别关键成分和枢纽基因。使用 Metascape 数据库进行基因本体论(GO)和京都基因与基因组百科全书(KEGG)途径富集分析,以揭示机制。此外,使用 AutoDock Vina 软件进行分子对接模拟,以评估关键成分和枢纽基因的亲和力。
筛选出 5 种关键成分和 6 个枢纽基因。这 6 个枢纽基因与 PI3K/AKT 或 ERK1/2 途径密切相关。KEGG 途径主要涉及 TNF 信号通路、钙信号通路和癌症相关通路。GO 富集分析结果表明,DHP 可能通过上述三种途径作用于生物过程,包括通过正调节激酶活性和细胞对含氮化合物的反应来治疗 CHF。最后,分子对接结果表明,五种关键成分与六种枢纽基因具有很强的亲和力。
本研究揭示了 DHP 中的类黄酮可能通过调节 TNF 途径及其下游 PI3K/Akt 或 ERK1/2 信号通路来缓解内皮功能障碍和心肌肥厚,或者通过调节钙信号通路改善兴奋-收缩偶联,从而改善 CHF 的分子机制。这些结果为进一步实验研究其药理作用提供了依据。